Anixa Biosciences CEO Amit Kumar buys $17,350 in company stock By Investing.com

Amit Kumar, Chief Executive Officer and a Director at Anixa Biosciences Inc (), acquired 5,000 shares of the company’s common stock on July 31, 2026. The transaction totaled $17,350, with shares purchased at a price of $3.47 each. The purchase came as the stock declined roughly 1% over the past week, though shares have gained about 14% over the past year.

Following this transaction, Mr. Kumar directly holds 657,000 shares of Anixa Biosciences common stock. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though analysts maintain a bullish outlook with price targets ranging from $7 to $14. The platform offers 7 additional ProTips and comprehensive financial metrics for deeper analysis of ANIX’s investment potential.

In other recent news, Anixa Biosciences Inc. has announced that it has dosed the first patient in the highest cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. This trial, conducted at Moffitt Cancer Center, is testing the highest dose level yet, with a focus on the follicle stimulating hormone receptor expressed on ovarian cancer cells. Additionally, Anixa has received a South Korean patent for its breast cancer vaccine technology, providing protection through 2040. This patent, exclusively licensed from Cleveland Clinic, covers the company’s innovative approach to breast cancer prevention and treatment.

Anixa also presented final Phase 1 data for its breast cancer vaccine at the New York Academy of Sciences’ symposium, showing that all major primary endpoints were met, with immune responses generated in 74% of participants. The vaccine was deemed safe and well tolerated at the maximum tolerated dose. In financial news, H.C. Wainwright reiterated a Buy rating with a $7.00 price target following Anixa’s fiscal second-quarter results. The company reported a net loss of $2.5 million, or $0.07 per share, and held $13.7 million in cash and investments as of the end of April 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.